There are limited treatment options in the first-line setting for patients with advanced ovarian cancer. Many patients experience disease recurrence or progression with first-line chemotherapy, with approximately 10% to 30% experiencing long-term survival.
Anti-angiogenesis agents, such as bevacizumab and nintedanib, have been investigated in clinical trials for the first-line treatment of patients with advanced ovarian cancer. Bevacizumab is now FDA approved in combination with carboplatin and paclitaxel, followed by bevacizumab as a single agent, for the treatment of women with stage III or stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection.
AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent grand rounds series on anti-angiogenesis agents for the first-line treatment of advanced ovarian cancer.